What question did this study set out to answer?

To evaluate the effects of clarithromycin on symptom relief and inflammation in mild COVID-19 pneumonia.

March 17, 2026Therapeutic Advances in Infectious Disease0 citationsOpen Access

Symptom relief and cytokine modulation by clarithromycin in mild COVID-19 pneumonia: an exploratory, multicenter, randomized-controlled open-label trial (CAME-COVID study)

KYKazuko Yamamoto NINaoki Iwanaga AUAsuka Umemura

Key Points

To evaluate the effects of clarithromycin on symptom relief and inflammation in mild COVID-19 pneumonia.
Multicenter, randomized-controlled, open-label trial
Enrolled patients with mild COVID-19 pneumonia in Japan
Compared groups receiving clarithromycin (800 mg/day or 400 mg/day) vs. standard treatment
Primary endpoint: days for 50% symptom improvement; secondary endpoints: cytokines and viral load
No significant difference in primary endpoint across groups
Symptoms tended to improve faster with 800 mg clarithromycin
Significant decrease in fatigue in the 800 mg group
Inflammatory cytokines decreased significantly in the 800 mg group
Mild gastrointestinal and liver events reported in the clarithromycin group

Abstract

Background: Coronavirus disease 2019 (COVID-19) remains an epidemic worldwide, and long COVID is a major social concern. Therapeutic options for relieving symptoms of COVID-19 pneumonia are limited. Clarithromycin (CAM), a macrolide antimicrobial, also functions as an immunomodulator. Objectives: To assess the efficacy of CAM in improving clinical symptoms and attenuating inflammation in patients with mild COVID-19, with the aim of preventing progression to severe disease. Design: An exploratory, multicenter, randomized-controlled, open-label trial. Methods: This trial enrolled patients with mild COVID-19 pneumonia without oxygen supplementation from May 2021 through February 2022 in eight hospitals in Japan. Patients were randomly assigned in a 1:1:1 ratio to groups A (CAM 800 mg/day, 7 days), B (CAM 400 mg/day, 7 days), or C (standard treatment). The primary endpoint was the number of days required for 50% improvement in seven symptoms (fatigue, headache, cough, shortness of breath, taste/smell disturbance, and general unwellness) based on severity scores. Secondary endpoints included inflammatory cytokines, viral load, immunoglobulins, and pneumonia infiltrations. Results: A total of 56 patients were enrolled and randomized. The primary endpoint did not differ significantly between groups (A: 5.0 days, B: 4.0 days, C: 4.0 days), though the seven symptoms tended to disappear earlier in group A than group C ( p = 0.08), and fatigue significantly decreased in group A ( p = 0.005). Serum inflammatory cytokines, tumor necrosis factor (TNF)-α, granulocyte colony stimulating factor (G-CSF), interleukin (IL)-7, IL-15, and proliferation factors, transforming growth factor (TGF)-α, fibroblast growth factor (FGF)-2, and fms-like tyrosine kinase 3 ligand (Flt3-L), significantly decreased in group A. IL-8 and IFN-γ in nasal drip significantly decreased in both group A and B. Serious adverse events did not increase in CAM groups, though mild gastrointestinal and liver events occurred in group A. Conclusion: CAM is safe and potentially useful for improving partial COVID-related symptoms and exerting immunomodulation during COVID-19 pneumonia. Trial registration: Japan Registry of Clinical Trials (jRCT; registration number: jRCTs071210011; https://jrct.mhlw.go.jp/latest-detail/jRCTs071210011 ) on April 13, 2021.

KI fragen

Bookmark

View Full Paper